| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk |
ChiCTR-IPR-15006834: The efficacy and safety for T2DM patients with OAD losing efficacy receiving insulin aspart 30 plus metformin compared with insulin aspart 30 monotherapy |
|
|
| Recruiting | 4 | 256 | | insulin aspart 30 (NovoMix30) and metformin (Glucophage) combination group ;insulin aspart 30 (NovoMix30) monotherapy group | Beijing Hospital; Beijing Hospital, Merck Serono | T2DM | | | | |
ChiCTR1900021970: Efficacy and safety of beinaglutide (formerly known as benaglutide) versus insulin aspart 30 as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin alone: a prospective, multi-centric, randomized, open-labeled, parallel-group study. |
|
|
| Recruiting | 4 | 420 | | benaglutide plus metformin ;biphasic insulin aspart 30 plus metformin | Peking University People's Hospital; Shanghai Benemae Pharmaceutical Corporation, Shanghai Benemae Pharmaceutical Corporation | Type 2 Diabetes | | | | |
ChiCTR2200062688: A randomized, double-blinded, parallel-controlled clinical study to investigate the blood glucose fluctuation of mulberry twig (Ramulus Mori, Sangzhi) alkaloid tablet in patients with Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 4 | 150 | | investigational product+NovoMix30 ;placebo+NovoMix30 | Tianjin Medical University Chu Hsien-I Memorial Hospital; Tianjin Medical University Chu Hsien-I Memorial Hospital, Beijing Wuhe Bo'ao Pharmaceutical Co., Ltd | Type 2 Diabetes Mellitus | | | | |
2005-004775-38: A comparison of pharmacodynamics and pharmacokinetics of Insulin Aspart and Biphasic Insulin Aspart 30, 50 og 70. A quadruple cross-over trial. |
|
|
| Ongoing | 3/4 | 24 | Europe | Bifasisk insulin aspart 30 (BIAsp 30), Insulin Aspart, Bifasisk Insulin Aspart 50, Bifasisk insulin Aspart 70, BIAsp 50, BIAsp 70, | Medicinsk Afd. M, Århus Sygehus, Nørrebrogade | Patients with type 1 diabetes | | | | |
2006-000305-35: A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up |
|
|
| Ongoing | 3 | 55 | Europe | Technosphere®/Insulin, Lantus 100 IU/ml, NovoMix 30 Penfill 100 U/ml, Lantus 100 IU/ml, NovoMix Penfill 100 U/ml, Lantus 100 IU/ml, NovoMix Penfill 100 U/ml | MannKind Corporation | Diabetes mellitus type II | | | | |
2017-000092-84: Comparison of SAR341402 Mix 70/30 to NovoMix 30 in Adult Patients with Diabetes Mellitus Using Pre-Mix Insulin Analogs. |
|
|
| Not yet recruiting | 3 | 600 | Europe | SAR341402, Suspension for injection, Suspension for injection in pre-filled pen, NovoMix 30 | Sanofi-aventis recherche & développement, Sanofi-aventis recherche & développement | Type 1 Diabetes MellitusType 2 Diabetes Mellitus, Type 1 Diabetes MellitusType 2 Diabetes Mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
CORRECT, NCT02587741: Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens |
|
|
| Recruiting | 1 | 600 | RoW | Metformin, gliclazide modified release tablets, acarbose, Lantus, Novomix30 | Third Affiliated Hospital, Sun Yat-Sen University | Diabetic Retinopathy | 07/23 | 07/25 | | |
ChiCTR1800020301: Add long-acting insulin or premixed insulin after oral antidiabetic drugs failing to reach HbA1c target: a randomized, cross-over trial |
|
|
| Not yet recruiting | N/A | 50 | | Glargine - Asp30 ;Asp30-IGlar | The Second Affiliated Hospital of Guangzhou Medical University; Level of the institution：, Guangzhou medical and health science and technology project (project number: 20171A11301) | Type 2 diabetes | | | | |
